At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
sorafenibdrug
Likely dose
Sorafenib 800 mg orally once daily until progressionAI-extracted
Key inclusion· 7
- ✓Histologically confirmed soft tissue sarcoma of specific types: angiosarcoma (cutaneous or visceral), malignant hemangiosarcoma, malignant hemangiopericytoma, or grade 3-4 leiomyosarcoma or liposarcoma
- ✓Unresectable residual, metastatic, or recurrent disease documented by radiography
- ✓Measurable disease by imaging or physical examination
- ✓Archived paraffin-embedded tumor sections available
Key exclusion· 9
- ✕Known brain metastases
- ✕History of thromboembolic disease
- ✕Uncontrolled hypertension
- ✕Prior sorafenib or inhibitors of VEGFR or MAPK pathway
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating sorafenib for Sarcoma. Completed, enrolled 51 participants across 184 sites.
Detailed Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with advanced soft tissue sarcomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2005
Enrollment StartMar 2006
Primary CompletionApr 2008
Study CompletionSep 2012
TodayJul 2026
First PostedSep 22, 2005
Enrollment StartMar 1, 2006
Primary CompletionApr 1, 2008
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 20.8 years ago
Interventions
sorafenibdrug
800 mg per day, daily until progression